1. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules 
Christopher W. Seder, MD, John C. Kubasiak, MD, Ravi Pithadia, MD, Sanjib Basu, PhD, Cristina Fhied, MS, Imad Tarhoni, MS, MBBch, Edgar Davila, BS, Hanan Alnajjar, MD, Gary W. Chmielewski, MD, William H. Warren, MD, Michael J. Liptay, MD, Jeffrey A. Borgia, PhD 
The Annals of Thoracic Surgery 
Volume 100, Issue 2, Pages (August 2015)
DOI: /j.athoracsur
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Representative “box and whisker” plot for heparin-binding epidermal growth factor (HB-EGF) with groups broken into matched sizes for comparison of benign and malignant nodules. (Size of groups are benign less than 20 [n = 90]; T1a [n = 129]; benign, 20 to 30 mm [n = 20]; T1b [n = 64]; benign, 30 to 50 mm [n = 15]; T2a [n = 36]).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Receiver operator characteristics curves for optimal panel in the Mayo Clinic validation cohort. (Area under the curve [AUC] = 0.640 with a sensitivity of 95%, specificity of 44.3%.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions